BioMarin Pharmaceutical (BMRN) Competitors $65.66 +0.66 (+1.02%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BMRN vs. ALNY, BIIB, UTHR, NBIX, INCY, EXAS, EXEL, RGEN, MDGL, and HALOShould you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. BioMarin Pharmaceutical vs. Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Incyte Exact Sciences Exelixis Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Alnylam Pharmaceuticals (NASDAQ:ALNY) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations. Do institutionals and insiders believe in ALNY or BMRN? 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer ALNY or BMRN? BioMarin Pharmaceutical received 432 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.16% of users gave Alnylam Pharmaceuticals an outperform vote while only 74.54% of users gave BioMarin Pharmaceutical an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes113476.16% Underperform Votes35523.84% BioMarin PharmaceuticalOutperform Votes156674.54% Underperform Votes53525.46% Does the media refer more to ALNY or BMRN? In the previous week, Alnylam Pharmaceuticals had 9 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 5 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.38 beat Alnylam Pharmaceuticals' score of 0.62 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ALNY or BMRN? Alnylam Pharmaceuticals presently has a consensus price target of $298.09, suggesting a potential upside of 21.45%. BioMarin Pharmaceutical has a consensus price target of $94.20, suggesting a potential upside of 43.47%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.71BioMarin Pharmaceutical 0 Sell rating(s) 7 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.74 Which has more risk & volatility, ALNY or BMRN? Alnylam Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Is ALNY or BMRN more profitable? BioMarin Pharmaceutical has a net margin of 11.71% compared to Alnylam Pharmaceuticals' net margin of -15.86%. BioMarin Pharmaceutical's return on equity of 8.53% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-15.86% N/A -8.38% BioMarin Pharmaceutical 11.71%8.53%6.40% Which has higher earnings and valuation, ALNY or BMRN? BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.09B15.11-$440.24M-$2.62-93.68BioMarin Pharmaceutical$2.75B4.55$167.65M$1.6739.32 SummaryBioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 14 of the 19 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRN vs. The Competition Export to ExcelMetricBioMarin PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.39B$6.57B$5.07B$9.08BDividend YieldN/A2.97%4.87%4.21%P/E Ratio39.3210.5999.0517.15Price / Sales4.55195.041,121.17116.80Price / Cash36.8857.1641.5237.88Price / Book2.505.104.754.78Net Income$167.65M$151.51M$119.33M$225.60M7 Day Performance-0.53%-2.13%-1.86%-1.23%1 Month Performance3.50%-3.14%11.40%3.07%1 Year Performance-31.00%11.53%30.26%16.48% BioMarin Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRNBioMarin Pharmaceutical4.9838 of 5 stars$65.66+1.0%$94.20+43.5%-29.1%$12.39B$2.75B39.323,401Positive NewsHigh Trading VolumeALNYAlnylam Pharmaceuticals4.4124 of 5 stars$246.53+0.4%$298.09+20.9%+37.1%$31.80B$1.83B-93.682,100Analyst UpgradeBIIBBiogen4.6223 of 5 stars$151.25+0.8%$245.32+62.2%-41.0%$22.04B$9.61B13.697,570Analyst DowngradeUTHRUnited Therapeutics4.708 of 5 stars$370.95+2.5%$370.860.0%+59.5%$16.56B$2.76B16.221,168Analyst DowngradeInsider TradePositive NewsNBIXNeurocrine Biosciences4.8249 of 5 stars$134.00+5.8%$165.00+23.1%+12.6%$13.57B$2.24B35.791,400Analyst ForecastInsider TradePositive NewsINCYIncyte4.7042 of 5 stars$70.38+2.7%$76.13+8.2%+13.3%$13.56B$4.08B489.642,524Analyst ForecastEXASExact Sciences4.4854 of 5 stars$60.48-1.3%$72.94+20.6%-11.7%$11.19B$2.50B-52.356,600EXELExelixis4.5077 of 5 stars$36.01+2.8%$31.47-12.6%+43.4%$10.28B$2.08B22.461,310Analyst DowngradeAnalyst RevisionRGENRepligen4.0971 of 5 stars$160.24+2.4%$190.25+18.7%-19.7%$8.98B$639.92M-422.731,783Analyst ForecastPositive NewsMDGLMadrigal Pharmaceuticals4.2369 of 5 stars$310.87+2.1%$347.33+11.7%+39.5%$6.78BN/A-12.1490Positive NewsHALOHalozyme Therapeutics4.9948 of 5 stars$48.39+0.8%$61.11+26.3%+29.1%$6.16B$947.36M15.98390Analyst ForecastPositive News Related Companies and Tools Related Companies ALNY Competitors BIIB Competitors UTHR Competitors NBIX Competitors INCY Competitors EXAS Competitors EXEL Competitors RGEN Competitors MDGL Competitors HALO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BMRN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMRN Stock Alerts